[ Price : $8.95]
HHS secretary Robert F. Kennedy, Jr., says FDA is reviewing safety evidence relating to the medication abortion drug mifepristone.[ Price : $8.95]
FDA says the Risk Evaluation and Management Strategy program that has been in place since 2011 for Sanofis thyroid cancer drug Cap...[ Price : $8.95]
Capricor Therapeutics reaches agreement with FDA on the design and role of its HOPE-3 trial as it works to resubmit its BLA for De...[ Price : $8.95]
Hansa Biopharma says imlifidase met the primary endpoint in a pivotal Phase 3 study in kidney transplant patients.[ Price : $8.95]
FDA publishes a guide to its Electronic Submission Gateway NextGen Unified Submission Portal.[ Price : $8.95]
The latest University of Pennsylvania Annenberg Public Policy Center survey documents a significant drop since last fall in the pe...[ Price : $8.95]
FDA approves an Eli Lilly NDA for Inluriyo (imlunestrant, 200 mg tablets), an oral estrogen receptor antagonist for treating certa...[ Price : $8.95]
CBER posts 13 Form FDA-483s under the Freedom of Information Acts provision on frequently requested records.